Findings {#Sec1}
========

Background {#Sec2}
----------

Aberrant crypt foci (ACF) are considered the first identifiable preneoplastic lesion in CRC \[[@CR1]\]. ACF show features that support their potential role as premalignant lesions, such as dysplasia, monoclonality, and mutations, which are present in adenomas and carcinomas but not in normal colon mucosa \[[@CR2], [@CR3]\]. High-magnification chromoscopic colonoscopy can detect ACF *in vivo*\[[@CR4]\], and several studies using chromoendoscopy have shown a higher rate of ACF occurrence in patients with CRC and adenomas compared with healthy individuals \[[@CR4]\]. Accordingly, ACF (especially those located in the rectum) have been proposed as a potential biomarker for CRC risk \[[@CR5]\]. Histologically, ACF can be classified as hyperplastic or dysplastic \[[@CR6]\]. Data from single-center studies have suggested that dysplastic ACF may correlate with CRC risk, as there is an increased frequency of dysplastic ACF in individuals with a normal colon, patients with adenoma, and patients with CRC \[[@CR1]\]. However, other studies have shown conflicting findings regarding the clinical value of dysplastic ACF \[[@CR7]--[@CR9]\], and thus, the role of ACF in colorectal carcinogenesis is still under debate. Although rectal ACF have been suggested as potential biomarkers to identify individuals at high risk for CRC because of their specific histological and molecular features, this is still an area of uncertainty \[[@CR10]\].

Methylation of cytosine residues at CpG dinucleotides is a major epigenetic modification strongly associated with transcriptional silencing. Long interspersed element-1 (LINE-1) elements are a type of genomic repetitive elements that in their full-length form encode the retrotransposon machinery \[[@CR11]\]. LINE-1 methylation status is a well-known surrogate marker for genome-wide DNA methylation level. In normal cells, LINE-1 is heavily methylated \[[@CR12]\], whereas cancer cells show LINE-1 hypomethylation, leading to chromosomal instability \[[@CR13]\]. This phenomenon occurs early in the colorectal carcinogenesis \[[@CR14], [@CR15]\]. However, despite the gradual increase of hypomethylation in the adenoma--carcinoma sequence \[[@CR16]\], LINE-1 methylation in ACF has never been studied. Moreover, recent studies have reported a field defect in LINE-1 hypomethylation \[[@CR14], [@CR17], [@CR18]\], suggesting that LINE-1 methylation status in normal mucosa could be used to stratify CRC risk and tailor preventive strategies.

The aims of this study were to analyze the levels of LINE-1 methylation in rectal ACF compared with paired normal colorectal mucosa, and to investigate the putative field defect of LINE-1 hypomethylation by analyzing the normal mucosa of patients from three different CRC risk groups. The analysis was confined to rectal ACF because of their previously reported higher frequency compared with other colonic segments, in addition to their usefulness as CRC biomarkers based on the total number and histological characteristics \[[@CR14]\].

Subjects and methods {#Sec3}
====================

Subjects {#Sec4}
--------

A random selection of patients referred to our hospital for a diagnostic colonoscopy between 2008 and 2010 was prospectively included in this study. Colonoscopy was performed with high-definition endoscopes (H180; Olympus, Tokio, Japan). Based on the colonoscopy findings, individuals were classified into healthy control (n = 70), adenoma (n = 42), and colon cancer (CC) (n = 35) groups. The distal rectum (10 cm) was explored with narrow band imaging and then with high-resolution chromoendoscopy using methylene blue 0.5%. For each individual, biopsy samples of normal descending colon and rectal mucosa (with a minimum distance of 10 cm away from any lesion), and up to three ACF in the rectum were used for molecular analyses (Figure  [1](#Fig1){ref-type="fig"}). Patients with rectal cancer were excluded from the analysis in order to ensure that biopsies were taken at least 10 cm away from the colorectal neoplasia in all patients. Two different endoscopists registered the number and features of ACF, and two expert pathologists characterized all biopsies.Figure 1**Study design.** Flow chart summarizing the study design. Long interspersed element-1 (LINE-1) methylation analysis was performed in DNA extracted from aberrant crypt foci (ACF) and normal colorectal mucosa samples from three colon cancer risk groups (individuals with a normal colonoscopy, patients with adenomas, and patients with colon cancer).

The project was granted approval from institutional review board of the Hospital Clinic of Barcelona, and written informed consent was obtained from all participants.

DNA extraction {#Sec5}
--------------

ACF and normal mucosa biopsies were preserved at −80°C optimal cutting compound (OCT) and phosphate-buffered saline (PBS), respectively. DNA was extracted using an All Prep DNA/RNA Mini Kit (catalog number 80204; Qiagen, Hilden, Germany) following the manufacturer's recommendations. DNA and RNA were quantified using a NanoDrop Spectrophotometer ND-1000 (Thermo Fisher Scientific).

Bisulfite pyrosequencing and LINE-1 methylation analysis {#Sec6}
--------------------------------------------------------

Bisulfite treatment was performed using the EpiTect Bisulfite kit (catalog number 59104; Qiagen) following manufacturer's instructions. Methylation analysis of LINE-1 promoter was investigated using pyrosequencing-based methylation analysis \[[@CR15]\]. PCR was carried out in a 25 μl PCR mixture containing 12.5 μl of GoTaq Colorless Master Mix (catalog number M7142, Promega, WI, USA) (Reaction Buffer pH 8.5, 400 μM of each dNTP, and 3 mM MgC~l2~), 1 μl of Taq polymerase, 2 μl of forward primer (5′-TTTTGAGTTAGGTGTGGGATATA-3′), 2 μl of reverse biotinylated primer (5′-AAAATCAAAAAATTCCCTTTC-3′), and 100 ng of bisulfite-treated genomic DNA. PCR cycling conditions were 95°C for 15 minutes; 45 cycles of 94°C for 30 seconds, 55°C for 45 seconds, and 72°C for 45 seconds; and finally, 10 minutes at 72°C and 4°C forever. The biotinylated PCR product was purified and made single-stranded to act as a template in a pyrosequencing reaction as recommended by the manufacturer using Pyrosequencing Vacuum Tool (Qiagen, Hilden, Germany). In brief, the PCR product was bound to a Streptavidin Sepharose HP column, and the sepharose beads containing the immobilized PCR product were purified, washed, denatured using 0.2 M NaOH solution, and washed again. Then, 10 μM of pyrosequencing primer (5′AGTTAGGTGTGGGATATAGT-3′) was annealed to the purified single-stranded PCR product, and pyrosequencing was performed using a PSQ 96MA Pyrosequencing System (Qiagen). CpGenome Methylated DNA (catalog number S7821; Millipore, Darmstadt, Germany) was used as a positive control. Methylation level of LINE-1 elements was calculated as the mean percentage of the four CpG sites analyzed, as previously described \[[@CR19]\].

Statistical analysis {#Sec7}
--------------------

Distribution of LINE-1 methylation levels was assessed with the Shapiro--Wilks test, which showed that the data were not normally distributed (*P* = 0.017). Accordingly, the Wilcoxon signed-rank test was used for comparing average methylation levels of paired ACF and normal mucosa. When comparing global methylation between two independent groups and between more than two groups, the Mann--Whitney *U*-test and Kruskal--Wallis test, respectively, were used. LINE-1 methylation levels are expressed as median and interquartile range (IQR). All statistical analyses were performed using SPSS software (v20; IBM Inc., Armonk, NY, USA) and results were considered significant at *P \<*0.05.

Results {#Sec8}
=======

Baseline characteristics of patients and rectal ACF related to CRC risk group are detailed in Table  [1](#Tab1){ref-type="table"}. As shown, the adenoma group mainly comprised patients with advanced adenomas (mean size 12.3 ± 9.8 mm) located throughout the colorectum. Although 16 patients (40%) with adenoma had synchronous serrated polyps, the vast majority of them were small hyperplastic polyps located in the rectosigmoid colon, which are known to lack clinical significance.Table 1**Baseline characteristics of individuals and aberrant crypt foci in each colon cancer risk group**Control ( n = 70)Adenoma ( n = 42)Colon cancer ( n = 35)Sex, n (%)  -- Female48 (68.6%)17 (40.5%)13 (37.1%)  -- Male22 (31.4%)25 (59.5%)22 (62.9%)Age, years, mean ± SD58.1 ± 15.368.6 ± 9.966.8 ± 8.6Colon cancer location, n (%)  -- Sigmoid----21 (60%)  -- Descending----2 (5.7%)  -- Transverse----1 (2.9%)  -- Ascending----9 (25.7%)  -- Cecum----2 (5.7%)Colon cancer TNM stage, n (%)  -- I----10 (28.6%)  -- II----11 (31.4%)  -- III----13 (37.1%)  -- IV----1 (2.9%)Adenoma features (per patient)^a^  -- Tubular, n (%)--28 (70%)11 (31.4%)  -- Tubulovillous, n (%)--7 (17.5%)1 (2.9%)  -- Villous, n (%)--5 (12.5%)0 (0%)  -- High-grade dysplasia, n (%)--11 (27.5%)5 (14.3%)  -- Adenoma size, mean (mm) ± SD--12.3 ± 9.88.4 ± 5  -- Number of adenomas per patient, mean ± SD (range)--2.4 ± 2 (1 to 9)1.2 ± 1.2 (1 to 4)Advanced adenoma^b^, n (%)22 (55%)7 (20%)Adenoma location (per patient)^c^, n (%)  -- Rectum--12 (30%)2 (5.7%)  -- Sigmoid--10 (25%)3 (8.6%)  -- Descending--5 (12.5%)3 (8.6%)  -- Transverse--5 (12.5%)2 (5.7%)  -- Ascending--5 (12.5%)2 (5.7%)  -- Cecum--3 (7.5%)0 (0%)Serrated polyps features (per patient)^d^  -- Recto-sigmoid hyperplastic polyps, n (%)--12 (30%)3 (8.6%)  -- Proximal serrated polyps, n (%)^e^--4 (10%)5 (14.3%)  -- Serrated polyps ≥10 mm, n (%)--2 (5%)2 (5.7%)  -- Serrated polyps per patient, n, mean ± SD (range)--1.6 ± 0.8 (1 to 3)3.1 ± 3.4 (1 to 5)  -- Hyperplastic polyp, n (%)--15 (37.5%)8 (22.9%)  -- Sessile serrated adenoma, n (%)--1 (%)0 (0%)  --Traditional serrated adenoma, n (%)--0 (%)0 (0%)ACF for molecular study, n1177677Dysplastic ACF, n (%)24 (17.4%)23 (24%)17 (25%)Hyperplastic ACF, n (%)114 (82.6%)73 (76%)51 (75%)ACF, aberrant crypt foci; SD, standard deviation.^a^This referred to 40 individuals in the adenoma group for whom full pathological information about the adenomas was available.^b^Advanced adenoma: ≥10 mm in size, or presence of high-grade dysplasia or villous features.^c^In cases with \>1 adenoma, this referred to the location of the most advanced adenoma.^d^Included hyperplastic polyps, sessile serrated adenomas, and traditional serrated adenomas.^e^Proximal to the sigmoid colon.

Rectal ACF do not display LINE-1 hypomethylation {#Sec9}
------------------------------------------------

To test the role of rectal ACF as a potential precursor lesion, we analyzed the LINE-1 methylation levels in rectal ACF and paired normal rectal and descending colon mucosa from all patients. The median LINE-1 methylation level of up to three ACF for each patient was considered for statistical purposes using the Wilcoxon signed-rank test. As shown in Figure  [2](#Fig2){ref-type="fig"}A, our data indicated that overall, levels of LINE-1 methylation were higher in ACF than in normal rectal mucosa (80.02% (77.54 to 82.22) versus 76.13% (73.74 to 78.06); *P* \< 0.0001). In fact, only 20 subjects exhibited lower LINE-1 methylation in their rectal ACF compared with their normal mucosa, and LINE-1 in rectal ACF was not hypomethylated in any of the three risk groups (Figure  [2](#Fig2){ref-type="fig"}B). Likewise, similar results were observed for LINE-1 methylation levels when comparing rectal ACF and normal mucosa from descending colon \[80.02% (77.54 to 82.22) versus 78.42% (76.51 to 80.33\]; *P* = 0.0002) (see Additional file [1](#MOESM1){ref-type="media"}: Figure S1). We also performed these analyses stratifying by sex, with similar results for both males and females (see Additional file [2](#MOESM2){ref-type="media"}: Table S1). Interestingly, there were significant differences in LINE-1 methylation between dysplastic ACF and hyperplastic ACF \[81.46% (78.75 to 82.97) versus 79.54% (76.88 to 81.79); *P =* 0.031\].Figure 2**Long interspersed element-1 (LINE-1) methylation status in aberrant crypt foci (ACF) and normal rectal mucosa. (A)** LINE-1 methylation levels in ACF compared with normal rectal mucosa (NRM) samples. **(B)** ACF LINE-1 methylation levels compared with NRM samples stratified by risk group. Box-and-whisker plot indicating the median methylation level expressed as a percentage (horizontal line), 25th and 75th percentiles (box), and maximum and minimum levels (whiskers).

LINE-1 methylation levels in normal colorectal mucosa are similar in all CC risk groups {#Sec10}
---------------------------------------------------------------------------------------

To assess the LINE-1 field defect, we compared the methylation status of LINE-1 in the normal rectal and descending colon mucosa of individuals from the three CC risk groups (CC, adenoma and healthy controls). Because the healthy control group was significantly younger than the adenoma and CC groups (Table  [1](#Tab1){ref-type="table"}), we first excluded an age effect in the level of LINE-1 methylation in normal mucosa (see Additional file [3](#MOESM3){ref-type="media"}: Figure S2). As shown in Figure  [3](#Fig3){ref-type="fig"}A, methylation of LINE-1 in normal rectal mucosa was independent of the patient group \[healthy controls: 76.73% (73.23 to 78.22); adenoma: 75.34% (73.7 to 77.2); CC: 77.06% (75.04 to 79.23); *P =* 0.107\] (Table  [2](#Tab2){ref-type="table"}). Comparable results were obtained when normal mucosa from the descending colon was considered \[healthy controls: 77.67% (75.84 to 80.18); adenoma: 78.45% (77.37 to 79.92); CC: 80.30% (77.19 to 81.39); *P =* 0.147\] (Table  [2](#Tab2){ref-type="table"}). These analyses were also performed with stratification by sex, with similar results (see Additional file [2](#MOESM2){ref-type="media"}: Table S1).Figure 3**Evaluation of long interspersed element-1 (LINE-1) methylation in normal colorectal mucosa as a potential field defect. (A)** LINE-1 methylation levels in normal rectal mucosa (NRM) stratified by colon cancer (CC) risk group. **(B)** LINE-1 methylation levels in NRM compared with normal mucosa from the descending colon (NDM). Box-and-whisker plot indicating the median methylation level expressed as a percentage (horizontal line), 25th and 75th percentile (box), and maximum and minimum levels (whiskers).

###### 

**LINE-1 methylation levels in normal mucosa and aberrant crypt foci for each of the three groups of subjects**

                                          Healthy controls (n = 70)   Adenoma (n = 42)          Colon cancer (n = 35)     ***P*** value ^a^
  --------------------------------------- --------------------------- ------------------------- ------------------------- -------------------
  Normal rectal mucosa, n/N               62/70                       31/42                     24/35                     0.107
  Median (IQR)                            76.73% (73.23 to 78.22)     75.34% (73.7 to 77.2)     77.06% (75.04 to 79.23)   
  Normal descending colon mucosa, n/N     42/70                       38/42                     21/35                     0.147
  Median (IQR)                            77.67% (75.84 to 80.18)     78.45% (77.37 to 79.92)   80.30% (77.19 to 81.39)   
  Aberrant crypt foci, n/N                68/70                       38/42                     24/35                     0.409
  Median (IQR)                            79.41% (77.24 to 81.58)     80.32% (77.45 to 82.82)   81.37% (77.48 to 83.14)   
  Dysplastic aberrant crypt foci, n/N     15                          11                        9                         0.32
  Median (IQR)                            80.58% (78.54 to 82.37)     80.99% (79.15 to 83.07)   82.74% (79.83 to 83.43)   
  Hyperplastic aberrant crypt foci, n/N   53                          27                        24                        0.812
  Median (IQR)                            79.32% (76.94 to 81.54)     79.59% (76.80 to 82.22)   80.02% (76.50 to 82.55)   

IQR, interquartile range; n, number of samples analyzed in each group; N, total number of samples included in each group.

^a^Kruskal--Wallis test was used to assess the level of LINE-1 methylation between the three risk groups.

We also analyzed the potential field defect for LINE-1 methylation by stratifying the results by the distance of the lesion to the normal mucosa biopsies. As shown in Table  [3](#Tab3){ref-type="table"}, LINE-1 methylation levels in normal mucosa did not differ depending on the distance to the adenoma or CC.Table 3**LINE-1 methylation levels in normal mucosa stratifying by location of the neoplastic lesion**LINE-1 methylationPatients with proximal adenoma (n = 10) ^a^Patients with distal adenoma (n = 30) ^a^***P*** valuePatients with proximal ^a^ colon cancer (n = 11)Patients with distal colon cancer (n = 24) ^a^***P*** valueNormal rectal mucosa73.87% (72.47 to 75.90)76.06% (74.78 to 77.33)0.08777.59% (72.78 to 80.12)77.40% (75.70 to 79.79)0.794Normal descending mucosa80.72% (76.62 to 82.68)78.38% (76.55 to 80.01)0.17677.14% (75.59 to 80.06)78.59% (76.90 to 79.41)0.458LINE-1 methylation levels are expressed as median (interquartile range, IQR).^**a**^Referred to the splenic flexure.

LINE-1 methylation levels in normal mucosa differ between colonic segments {#Sec11}
--------------------------------------------------------------------------

Interestingly, when we compared the LINE-1 methylation status in normal mucosa from different segments of the colorectum, we found a higher degree of hypomethylation in the rectum compared with the descending colon \[76.13% (73.75 to 78.06) versus 78.42% (76.51 to 80.33); *P \<* 0.0001\], suggesting different genome-wide methylation profiles between normal colon and rectal mucosa (Figure  [3](#Fig3){ref-type="fig"}B). Stratification by sex did not vary the results (see Additional file [2](#MOESM2){ref-type="media"}: Table S1).

Discussion {#Sec12}
==========

Overall, our results argue against the hypothesis that global hypomethylation occurs at the earliest stages of colorectal carcinogenesis. Overexpression of β-catenin and *KRAS* mutations may indicate that ACF constitute a premalignant stage \[[@CR16]\]. Moreover, LINE-1 hypomethylation is already present at the adenoma stage \[[@CR15]\]. Our data suggest, for the first time, to our knowledge, that the formation of ACF is not triggered by hypomethylation in LINE-1 elements, and that genome-wide hypomethylation occurs after ACF formation, most likely during the transition from non-adenomatous to adenomatous epithelia. In fact, hypermethylation of LINE-1 elements in ACF suggests that reversal epigenetic changes occur in these lesions regardless of their pathogenic progression.

Despite the fact that two previous reports have suggested the existence of LINE-1 hypomethylation field defects in CRC, our results indicate the absence of this phenomenon in our sample set. Kamiyama and collaborators recently showed that normal colonic mucosa from patients with synchronous CRC displayed higher hypomethylation of LINE-1 compared with patients with solitary CRC and controls \[[@CR17]\]. However, and in line with our results, there were no differences between the two latter groups. Another study has shown that normal colorectal mucosa samples from different risk groups displayed differences in LINE-1 methylation that mirrored differences between their respective tumor specimens \[[@CR17]\]. A more recent study has shown that adjacent mucosa from individuals with multiple/large serrated polyps display significantly lower LINE-1 methylation levels compared with individuals without such polyps \[[@CR18]\]. We tested the hypothesis that LINE-1 methylation in normal mucosa could be used as a biomarker for risk of sporadic CRC, focusing on patients with conventional adenomas. By analyzing a prospective cohort of patients with CC and controls, we found that our data suggest that methylation status of LINE-1 in normal mucosa is not a suitable biomarker to predict CC risk in patients with sporadic cancer. However, the potential field defect for LINE-1 methylation in patients with serrated polyps needs further assessment. In addition, our data show different methylation levels in normal mucosa between the descending colon and the rectum, suggesting different methylation profiling depending on the colonic segment.

Conclusion {#Sec13}
==========

Our results shed some light on the role of genome-wide methylation in rectal ACF and argue against its utility as a biomarkers for assessing CC risk.
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Additional file 1: Figure S1: LINE-1 methylation status in aberrant crypt foci and normal mucosa from the descending colon. (A) LINE-1 methylation levels in aberrant crypt foci (ACF) compared to normal mucosa from the descending colon (NDM). (B) ACF LINE-1 methylation levels compared to descending mucosa samples according to risk group. Box-and-whisker plot indicating the median methylation level expressed as a percentage (horizontal line), 25^th^ and 75^th^ percentile (box), and maximum and minimum levels (whiskers). (TIFF 3 MB)
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Additional file 3: Figure S2: Evaluation of the age-effect for LINE-1 methylation data. Representation of the correlation between LINE-1 methylation levels in normal rectal mucosa and the age of patients. (TIFF 4 MB)
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